Thermally stable vaccine formulations and microneedles
Formulations and methods are provided for stabilizing antigens in dry solid vaccines. One aspect relates to dry solid formulations of influenza vaccines including one or more excipients identified as imparting stability to influenza antigens. Another aspect relates to dry solid formulations of measles vaccines including one or more excipients identified as imparting stability to a measles antigen. The formulations may be in a form suitable for reconstitution in a physiologically acceptable liquid vehicle to form an injectable solution or suspension for administration to a patient or in the form of dissolvable microneedles or coated microneedles.
1. A vaccine composition comprising:
an influenza antigen, and
an excipient selected from the group consisting of maltodextrin 17, maltodextrin 4, arginine, histidine, calcium heptagluconate, maltodextrin 13, heparin, raffinose, arabitol, fructose, potassium gluconate, adonitol, xylitol, sodium thiosulfate, asparigine, 2-hydroxypropyl-β-cyclodextrin, TRIS, sodium citrate, dulcitol, and combinations thereof,
wherein the composition is in a dry solid form which is in the form of a dissolvable microneedle or a dissolvable microneedle coating.
2. The vaccine composition of claim 1 , wherein the excipient is present in the composition in an amount from about 1% to about 90% by weight.
3. The vaccine composition of claim 1 , wherein the influenza antigen is selected from the group consisting of influenza A, influenza B, influenza C, and combinations thereof.
4. The vaccine composition of claim 1 , wherein the influenza antigen comprises a whole inactivated influenza virus, a split inactivated influenza virus, a subunit inactivated influenza virus, an influenza virus-like particle, or a combination thereof.
5. The vaccine composition of claim 1 , further comprising one or more adjuvants.
6. The vaccine composition of claim 1 , wherein the influenza antigen is characterized as having improved stability over six months in the composition as compared to a comparative composition comprising the influenza antigen without an excipient.
7. The vaccine composition of claim 1 , wherein the influenza antigen is characterized as having improved stability over three months in the composition as compared to a comparative composition comprising the influenza antigen without an excipient.
8. The vaccine composition of claim 1 , wherein the influenza antigen maintains at least 50% of its activity after three months of storage at temperatures up to 40° C.
9. The vaccine composition of claim 1 , wherein the influenza antigen maintains at least 75% of its activity after three months of storage at temperatures up to 40° C.
10. A vaccine composition comprising:
an influenza antigen, and
a blend of excipients selected from the group consisting of trehalose and arginine;
trehalose and calcium heptagluconate; trehalose and maltodextrin 13; sucrose and arginine; arginine and calcium heptagluconate; arginine and maltodextrin 13; calcium heptagluconate and maltodextrin 13; maltodextrin 13 and sodium citrate; maltodextrin 13 and lactose; and sorbitol and sodium citrate,
wherein the composition is in a dry solid form which is in the form of a dissolvable microneedle or a dissolvable microneedle coating.
11. The vaccine composition of claim 10 , wherein the blend of excipients is present in the composition in a total amount from about 1% to about 90% by weight.
12. The vaccine composition of claim 10 , wherein the excipients of the blend are present in the composition at a ratio from about 1:15 to about 15:1.
13. The vaccine composition of claim 10 , wherein the excipients of the blend are present in the composition at a ratio of about 1:1.
14. The vaccine composition of claim 10 , wherein the influenza antigen is selected from the group consisting of influenza A, influenza B, influenza C, and combinations thereof.
15. The vaccine composition of claim 10 , wherein the influenza antigen comprises a whole inactivated influenza virus, a split inactivated influenza virus, a subunit inactivated influenza virus, an influenza virus-like particle, or a combination thereof.
16. The vaccine composition of claim 10 , further comprising one or more adjuvants.
17. The vaccine composition of claim 10 , wherein the influenza antigen is characterized as having improved stability over six months in the composition as compared to a comparative composition comprising the influenza antigen without one or more excipients.
18. The vaccine composition of claim 10 , wherein the influenza antigen is characterized as having improved stability over three months in the composition as compared to a comparative composition comprising the influenza antigen without one or more excipients.
19. The vaccine composition of claim 10 , wherein the influenza antigen maintains at least 50% of its activity after three months of storage at temperatures up to 40° C.
20. The vaccine composition of claim 10 , wherein the influenza antigen maintains at least 75% of its activity after three months of storage at temperatures up to 40° C.
21. A vaccine composition comprising:
an influenza antigen, and
an excipient blend comprising sucrose and arginine,
wherein the composition is in a dry solid form, and is in the form of a dissolvable microneedle or a microneedle coating.
22. A transdermal patch comprising a base and an array of microneedles which extend from the base and comprise the vaccine composition of claim 1 .
23. A method of vaccinating a patient comprising:
inserting one or more microneedles across the stratum corneum of the patient's skin, wherein the one or more microneedles comprise the vaccine composition of claim 1 ,
wherein the vaccine composition dissolves in vivo over a dissolution period from about 1 second to about 1 hour.
24. A vaccine composition comprising:
an influenza antigen,
an excipient selected from the group consisting of maltodextrin 17, maltodextrin 4, arginine, maltose, histidine, calcium heptagluconate, maltodextrin 13, heparin, raffinose, myo-inositol, sucrose, sorbitol, arabitol, fructose, potassium gluconate, adonitol, xylitol, sodium thiosulfate, asparigine, 2-hydroxypropyl-β-cyclodextrin, TRIS, sodium citrate, dulcitol, and combinations thereof, and
a buffer salt comprising HEPES, ammonium acetate, or potassium phosphate dibasic,
wherein the composition is in a dry solid form which is in the form of a dissolvable microneedle or a dissolvable microneedle coating.
25. The vaccine composition of claim 10 , wherein the composition further comprises HEPES, ammonium acetate, or potassium phosphate dibasic.
26. The vaccine composition of claim 21 , wherein the composition further comprises HEPES, ammonium acetate, or potassium phosphate dibasic.
27. A vaccine composition comprising:
an influenza antigen;
an excipient selected from sucrose, trehalose, arginine, maltodextrin, calcium heptagluconate, and combinations thereof; and
a buffer salt selected from HEPES, ammonium acetate, and potassium phosphate dibasic,
wherein the composition is in a dry solid form which is in the form of a dissolvable microneedle or a dissolvable microneedle coating.